BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1219@pharmaconomics
DTSTAMP:20260707T033904Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:ABVX Phase 3 — obefazimod
DESCRIPTION:Phase 3 trial results for obefazimod in ulcerative colitis are due Jun 29\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1956827/000195682726000022/a6-kpressreleaseq12026fina.htm\n\nTrack it: https://pharmaconomics.com/e/1219
URL:https://pharmaconomics.com/e/1219
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ABVX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR